ANGPTL3 and fatty liver disease: In participants with hepatic steatosis, repeat dosing at the same time point was associated with decreases in ANGPTL3 by 85%, TG by 44%, non–HDL-C by 37%, LDL-C by 35%, and apoB by 20%.